An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentric experimental comparative evaluation of two formulations of Quetiapine extended release tablets 400 mg under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 02 Oct 2010 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India record.
- 09 Feb 2010 New trial record